By Malvika Gurung Investing.com -- Shares of the pharmaceutical company Natco Pharma (NS:NATP) traded 3.8% higher at 10 am, after zooming 9% in early trade on Tuesday, in response to the...
By Malvika Gurung Investing.com -- Larsen & Toubro (NS:LART): The engineering and construction major launched its own B2B e-commerce platform, called L&T SuFin. Axis Bank (NS:AXBK): The...
By Malvika Gurung Investing.com -- ONGC (NS:ONGC): The state-run gas major reported a whopping 596.7% YoY jump in net profit at Rs 8,764 crore in the December ending period after higher oil...
By Malvika Gurung Investing.com -- After opening almost 1% lower on Monday, following mixed cues from Asian markets, Indian equity benchmark indices Nifty50 and BSE Sensex have pared losses...
By Aditya Raghunath Investing.com -- The second wave of the coronavirus keeps mutating and its side effects are as bad as the disease itself. While the number of infections has been steadily...
(Adds details on the drug, background)BENGALURU, May 5 (Reuters) - India has given emergency use authorization for a COVID-19 antibody drug cocktail developed by Roche ROG.S and Regeneron...
May 3 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO RECEIVES EMERGENCY USE APPROVAL FOR BARICITINIB TABLETS FOR COVID-19 TREATMENT* NATCO WILL BE REQUESTING A COMPULSORY LICENSE BASED ON...
March 26 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD - TO ACQUIRE 0.96% STAKE IN NATCO PHARMA (CANADA) INC...
March 15 (Reuters) - Natco Pharma Ltd NATP.NS :* FORAYS INTO PHEROMONE BASED TECHNOLOGY FOR INTEGRATED PEST MANAGEMENT* DURING KHARIF 2021, NATCO PLANS TO LAUNCH ITS FIRST GREEN LABEL...
Feb 26 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD SAYS LAUNCHES BRIVARACETAM TABLETS, IN INDIA, FOR TREATMENT OF EPILEPSY...
Feb 11 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD DEC-QUARTER CONSOL PROFIT 627 MILLION RUPEES VERSUS 1.05 BILLION RUPEES YEAR AGO* NATCO PHARMA LTD DEC-QUARTER CONSOL...
Dec 17 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD - LAUNCHES ANTI BLOOD CLOT TABLET RIVAROXABAN IN INDIA...
Nov 12 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD SEPT-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES VERSUS 1.19 BILLION RUPEES YEAR AGO* NATCO PHARMA LTD SEPT-QUARTER CONSOL...
Sept 10 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA -PURCHASE OF SHARES IN UNIT AMOUNTING TO $727,100...
Aug 12 (Reuters) - Natco Pharma Ltd NATP.NS :* JUNE-QUARTER CONSOL PROFIT 1.22 BILLION RUPEES VERSUS PROFIT 1.43 BILLION RUPEES YEAR AGO* JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.63...
May 22 (Reuters) - Natco Pharma Ltd NATP.NS :* DONATING CHLOROQUINE PHOSPHATE TABLETS, THROUGH U.S. MARKETING PARTNER, TO COLUMBIA UNIVERSITY* DONATION FOR COLUMBIA UNIVERSITY'S...
April 28 (Reuters) - Natco Pharma Ltd NATP.NS :* VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL...
March 6 (Reuters) - Natco Pharma Ltd NATP.NS :* U.S. FDA COMPLETES INSPECTION OF NATCO'S KOTHUR FORMULATION FACILITY* KOTHUR FORMULATION FACILITY GOT SINGLE OBSERVATION RELATED TO...
Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS :* DEC QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES VERSUS 1.6 BILLION RUPEES YEAR AGO* DEC QUARTER CONSOL REVENUE FROM OPERATIONS 4.82 BILLION...
Jan 2 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD - FILES ANDA FOR TRIFLURIDINE/ TIPIRACIL HYDROCHLORIDE TA BLETS FOR USA MARKET* NATCO PHARMA LTD - BELIEVES THAT IT IS ONE OF...
Nov 14 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO PHARMA LTD - COMMERCIAL MANUFACTURING OPERATIONS BEGIN IN NATCO'S VISAKHAPATNAM FORMULATION...
Nov 12 (Reuters) - Natco Pharma Ltd NATP.NS :* SEPT QUARTER CONSOL NET PROFIT 1.19 BILLION RUPEES VERSUS 1.83 BILLION RUPEES YEAR AGO* SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 4.86...
Nov 11 (Reuters) - Natco Pharma Ltd NATP.NS :* ANNOUNCES PRODUCT FROM CROP HEALTH SCIENCES DIVISION FOR CHLORANTRANILIPROLE; CO AWAITING REGULATORY APPROVAL OF THE...
Oct 1 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR MEKAGUDA'S ACTIVE PHARMACEUTICAL INGREDIENT...
Aug 23 (Reuters) - Natco Pharma Ltd NATP.NS :* RAISES STAKE IN OMRV HOSPITALS PVT LTD TO 12.81% FROM...
Aug 12 (Reuters) - Natco Pharma Ltd NATP.NS :* USFDA COMPLETES INSPECTION OF NATCO'S MEKAGUDA ACTIVE PHARMACEUTICAL INGREDIENT FACILITY* FACILITY RECEIVED SIX OBSERVATIONS* NONE OF...
Aug 9 (Reuters) - Natco Pharma Ltd NATP.NS :* JUNE QUARTER CONSOL NET PROFIT 1.43 BILLION RUPEES VERSUS 1.82 BILLION RUPEES YEAR AGO* JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 4.92...
Aug 5 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR KOTHUR FACILITY* GETS EIR FROM USFDA FOR INSPECTION CONDUCTED AT KOTHUR DRUG FORMULATIONS...
June 6 (Reuters) - Natco Pharma Ltd NATP.NS :* SAYS U.S. FDA COMPLETES INSPECTION OF CO'S KOTHUR FORMULATION FACILITY* SAYS FACILITY RECEIVED NINE OBSERVATIONS, WITH NO REPEAT...
May 30 (Reuters) - Natco Pharma Ltd NATP.NS :* SAYS NATCO SETTLES GENERIC CARFILZOMIB INJECTION PATENT LITIGATION IN US MARKET* SAYS THE PARTIES HAVE REACHED A SETTLEMENT AGREEMENT AND THE...
May 27 (Reuters) - Natco Pharma Ltd NATP.NS :* MARCH QUARTER CONSOL NET PROFIT 1.2 BILLION RUPEES VERSUS 3 BILLION RUPEES YEAR AGO* MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 4.56...
May 2 (Reuters) - Natco Pharma Ltd NATP.NS :* GOT ANDA APPROVAL FROM USFDA FOR BOSENTAN TABLETS IN STRENGTHS OF 62.5 MG AND 125 MG...
Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS :* DEC QUARTER CONSOL NET PROFIT 1.60 BILLION RUPEES VERSUS PROFIT 2.18 BILLION RUPEES YEAR AGO* DEC QUARTER CONSOL REVENUE FROM OPERATIONS 5.57...
Jan 28 (Reuters) - Natco Pharma Ltd NATP.NS :* SAYS NATCO LAUNCHES VALSARTAN/SACUBITRIL TABLET IN INDIA* SAYS DRUG IS USED FOR CERTAIN TYPES OF HEART FAILURE...
Jan 25 (Reuters) - Natco Pharma Ltd NATP.NS :* SAYS NATCO INITIATES GREENFIELD FACILITIES FOR NICHE AGRICHEMICAL BUSINESS* SAYS FACILITIES WILL MANUFACTURE BOTH AGRICHEMICAL TECHNICAL AND...
Nov 5 (Reuters) - Natco Pharma Ltd NATP.NS : * SEPT QUARTER CONSOL NET PROFIT 1.83 BILLION RUPEES VERSUS PROFIT 848 MILLION RUPEES YEAR AGO * SEPT QUARTER CONSOL REVENUE FROM OPERATIONS...
Oct 29 (Reuters) - Natco Pharma Ltd NATP.NS : * SAYS TO CONSIDER BUY-BACK OF EQUITY SHARES OF COMPANY AND RELATED...
Oct 15 (Reuters) - Natco Pharma Ltd NATP.NS : * U.S. COURT OF APPEALS AFFIRMED DISTRICT OF DELAWARE'S DECISION THAT TEVA'S COPAXONE 40 MG/ML DOSING PATENTS ARE INVALID AS...
Aug 13 (Reuters) - Natco Pharma Ltd NATP.NS :* SAYS DR.REDDY'S & CO FILE DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION IN EUROPE...
Aug 8 (Reuters) - Natco Pharma Ltd NATP.NS : * JUNE QUARTER CONSOL NET PROFIT 1.82 BILLION RUPEES VERSUS PROFIT 940 MILLION RUPEES YEAR AGO * JUNE QUARTER CONSOL REVENUE FROM OPERATIONS...
July 2 (Reuters) - Natco Pharma Ltd NATP.NS : * SAYS LAUNCHES FIXED DOSE COMBINATION OF SOFOSBUVIR-DACLATASVIR DRUG FOR HEPATITIS C TREATMENT IN...
June 8 (Reuters) - Natco Pharma Ltd NATP.NS : * SAYS CO LAUNCHES GENERIC POSACONAZOLE INJECTION IN...
May 23 (Reuters) - Natco Pharma Ltd NATP.NS : * MARCH QUARTER CONSOL PROFIT 3 BILLION RUPEES VERSUS PROFIT 1.77 BILLION RUPEES YEAR AGO * MARCH QUARTER CONSOL REVENUE FROM OPERATIONS...
March 1 (Reuters) - Natco Pharma Ltd NATP.NS : * SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FORSOFOSBUVIRTABLETS, 400MG, WITH U.S. FDA * SAYS DRUG IS USED FOR TREATMENT OF...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
